Trials / Completed
CompletedNCT00111774
Evaluating ABX-EGF in Patients With Metastatic ColorectalCarcinoma
An Open Label Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of ABX-EGF in Patients With Metastatic Colorectal Carcinoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 150 (planned)
- Sponsor
- Amgen · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine if ABX-EGF is safe and efficacious in patients with metastatic colorectal cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ABX-EGF |
Timeline
- Start date
- 2002-03-01
- First posted
- 2005-05-26
- Last updated
- 2013-05-14
Source: ClinicalTrials.gov record NCT00111774. Inclusion in this directory is not an endorsement.